Evidence map›Paper›PMID 40076243›Full record

ReviewMolecules (Basel, Switzerland)2025

The Role of Ferulic Acid in Selected Malignant Neoplasms.

Anna Markowska, Janina Markowska, Joanna Stanisławiak-Rudowicz, Katarzyna Kozak, Otton Krzysztof Roubinek, Magdalena Jasińska

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Development and Characterization ofLife (Basel, Switzerland) · 2026
    Article
  6. Enhanced cytotoxic activity ofNanoscale advances · 2026
    Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anna MarkowskaDepartment of Perinatology, Poznań University of Medical Science, 60-535 Poznań, Poland.ORCID 0000-0002-4078-6568
Janina MarkowskaGynecologic Oncology Center Poznań, Poznańska 58A, 60-850 Poznań, Poland.ORCID 0000-0002-2893-8389
Joanna Stanisławiak-RudowiczDepartment of Gynecologic Oncology, Poznań University of Medical Sciences, Szamarzewskiego 84, 60-514 Poznań, Poland.
Katarzyna KozakŁukasiewicz Research Network-Industrial Chemistry Institute, Rydygiera 8, 01-793 Warszawa, Poland.ORCID 0000-0003-0706-3568
Otton Krzysztof RoubinekŁukasiewicz Research Network-Industrial Chemistry Institute, Rydygiera 8, 01-793 Warszawa, Poland.
Magdalena JasińskaFaculty of Chemical and Process Engineering, Warsaw University of Technology, Waryńskiego 1, 00-645 Warszawa, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferulic acid (FA) is a polyphenol that is found in plants and fruits. It has a wide range of anticancer properties, including participating in cell apoptosis, inhibiting invasion and angiogenesis, and acting synergistically with standard cytostatic agents in malignant tumors. A range of molecular mechanisms are involved in anticancer activity and include the following ones: activation of cell-cycle-related proteins and enzymes such as p53, p21, Bax, and pro-caspases 3 and 9, reduction of cyclin D1 and E, proapoptotic Bcl-2, MMP-9, and NF-kV, which decrease VEGF, leading to cell cycle arrest at G0/G1 phase and death of cancer cells. Other mechanisms inhibit several pathways: PI3K/AKT/mTOR, Notch, and Wnt, which are associated with downregulation of proliferation, invasion, metastasis, and angiogenesis. FA can induce activation of ROS, leading to DNA damage in cancer cells. In vitro and in vivo studies have demonstrated the significant antitumor activity of FA in breast cancer, particularly when used in combination with cytostatic agents. In vitro studies on cervical cancer cell lines have reported similar anticancer activity of FA. This includes inhibition of cell proliferation and induction of apoptosis by downregulating antiapoptotic proteins. A case-control study conducted in Italy found that men with histologically confirmed prostate cancer had notably lower levels of FA compared to controls. Molecular in vitro studies have suggested that FA may have various effects on the signaling pathways linked to a reduction in the risk of prostate cancer, and it may act in synergy with δ-tocotrienol, which is a derivative of vitamin E. In vivo and in vitro studies on colorectal cancer have demonstrated the effects of FA on the early development of this cancer-inhibition of abnormal crypt foci (ACF-aberrant crypt foci), as well as the reduction in cancer cell viability and apoptosis through molecular changes, mainly a decrease in EGFR expression. The poor water solubility of FA makes it an attractive candidate for use as nanoparticles.

Indexed as

Coumaric AcidsNeoplasmsAnimalsApoptosisCell ProliferationFemaleHumansMaleSignal TransductionCoumaric Acidsferulic acidanticancer activitybreast cancercervical cancercolon cancerferulic acid (FA)flavonoidsprostate cancer

Identifiers

PMID40076243
PMCPMC11901789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.